Heartbeam, Inc. (BEAT) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Health Information Services) last closed at $0.48. The rating moved from Neutral to Oversold on August 15, 2026.

• Public ratingOversold (as of August 19, 2026)
• Last close$0.48
• Last changeMoved from Neutral to Oversold on August 15, 2026
• SectorHealthcare
• IndustryHealth Information Services

See all oversold Healthcare stocks →

AI analysis

Heartbeam is an early-stage cardiac diagnostics company with a potentially differentiated monitoring technology but limited near-term revenue and a small-cap balance sheet. Positive sector interest in diagnostics and any favorable clinical or partnership updates could provide upside, while financing needs, regulatory hurdles, and competitive pressures represent the main execution risks. Short-term price action is likely to remain driven by news flow, liquidity, and funding developments rather than steady fundamental cash generation.

Key factors

• Early-stage medtech with a focused product set targeting cardiac diagnostic monitoring and ischemia detection
• Differentiated technology potential if validated clinically and adopted by providers/EMR workflows
• Operating at a microcap/low-liquidity market capitalization with correspondingly volatile share behavior
• Sector backdrop shows interest in diagnostics and screening which could support commercial partnerships or BD activity
• Near-term value drivers include clinical data readouts, regulatory milestones, reimbursement signals, and partnership announcements

Risks

• Limited financial runway and recurring need for capital raising leading to dilution risk
• Regulatory or clinical setbacks that delay commercialization or limit indicated uses
• Adoption and reimbursement uncertainty for new cardiac diagnostic devices in fragmented provider payment systems
• Strong competition from established cardiac monitoring and diagnostic firms with larger salesforces and distribution
• Low daily trading volume and thin liquidity that can amplify price moves and increase execution risk for shareholders

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.